ClinicalTrials.gg
RecruitingNCT07537127Updated Nov 12, 2026

Lidocaine for LESS Postoperative Shoulder Pain Alleviation

An interventional study of subdiaphragmatic lidocaine sprayed and standard ERAS in Cystectomy and Myomectomy, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 12, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

Objective: To evaluate the efficacy of subdiaphragmatic spray of 0.08% lidocaine in relieving postoperative acute pain and psychological status of patients undergoing single-port laparoscopic surgery for benign gynecological diseases, and to provide evidence-based basis for optimizing postoperative analgesic strategies.

Methods: A single-center, prospective randomized controlled study was conducted. A total of 100 patients scheduled for elective single-port laparoscopic surgery due to uterine fibroids, ovarian cysts, or other benign gynecological conditions were selected from the General Gynecology Center of Peking Union Medical College Hospital. They were divided into the experimental group (n=50) and the control group (n=50) using a random number table. The experimental group received 50 ml of 0.08% lidocaine solution sprayed on the bilateral subdiaphragmatic regions at the start of surgery, while the control group underwent standard ERAS without any pharmaceutical intervention in the subdiaphragmatic area. The primary endpoint was the Numerical Rating Scale (NRS) score for resting pain at 6 hours postoperatively. The secondary endpoints included NRS scores at 1, 2, 12, and 24 hours postoperatively, total consumption of analgesics within 48 hours after surgery, incidence of adverse reactions, patient satisfaction, and scores of psychological and sleep scales (Distress Thermometer, GAD-7, etc.) at 30 days postoperatively. SPSS 25.0 software was used for data analysis. Quantitative data were analyzed by t-test or Mann-Whitney U test, and qualitative data were analyzed by χ² test or Fisher's exact test. Repeated measurement data were analyzed by repeated measures analysis of variance.

Results: After the completion of the study, differences in NRS scores, analgesic consumption, psychological status and other indicators between the two groups will be compared.

Conclusion: The results of this study will clarify the clinical value of intraoperative diaphragmatic infiltration with low-concentration lidocaine in postoperative analgesia after single-port laparoscopic gynecological surgery, and provide references for postoperative pain management and psychological intervention.

02

Conditions studied

  • Cystectomy
  • Myomectomy
03

In context

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Female patients aged 18-65 years;
  • Clear preoperative diagnosis, suitable for single-port laparoscopic surgery, and (ASA) physical status classification I-II;
  • Patients or their family members can understand the study protocol, are willing to participate in the study, and provide written .

Exclusion criteria

Exclusion Criteria:

  • Allergy to lidocaine or amide-type local anesthetics;
  • Severe medical comorbidities;
  • Long-term preoperative use of opioid drugs or sedatives;
  • Pregnant or lactating women;
  • Conversion to laparotomy or addition of surgical ports during surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    subdiaphragmatic lidocaine spray

    After adjusting the patient's position, a catheter is inserted through the single-port laparoscopic operating channel, and 50ml of 0.08% lidocaine solution is evenly sprayed on the bilateral subdiaphragmatic regions under laparoscopic direct vision.

    Other: subdiaphragmatic lidocaine sprayed

  • Placebo comparator
    standard ERAS

    Standard Enhanced Recovery After Surgery (ERAS) protocol for single-port laparoscopic surgery is performed, with no drug intervention in the subdiaphragmatic region at the end of surgery.

    Procedure: standard ERAS

Interventions

  • Othersubdiaphragmatic lidocaine sprayed

    After adjusting the patient's position, a catheter is inserted through the single-port laparoscopic operating channel, and 50ml of 0.08% lidocaine solution is evenly sprayed on the bilateral subdiaphragmatic regions under laparoscopic direct vision.

  • Procedurestandard ERAS

    Standard Enhanced Recovery After Surgery (ERAS) protocol for single-port laparoscopic surgery is performed, with no drug intervention in the subdiaphragmatic region at the end of surgery.

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS) score at rest 6 hours postoperatively

    NRS: range from 0\~10, with 10 the heaviest pain

    Time frame: From operation to 6 hours after operation

Secondary outcomes

  1. NRS scores at rest 1, 2, 12, and 24 hours postoperatively

    NRS: range from 0\~10, with 10 the heaviest pain

    Time frame: from operation to 1, 2, 12, and 24 hours after operation

  2. Total consumption of postoperative analgesic drugs:type of additional postoperative analgesic drugs

    type of additional postoperative analgesic drugs used after operation, besides standard ERAS protocol

    Time frame: from operation to 48 hours after operation

  3. Total consumption of postoperative analgesic drugs: dosage of additional postoperative analgesic drugs

    dosage of additional postoperative analgesic drugs used after operation, besides standard ERAS protocol

    Time frame: from operation to 48 hours after operation

  4. Incidence of postoperative nausea and vomiting

    incidence of postoperative nausea or vomiting

    Time frame: from operation to 48 hours after operation

  5. Overall patient satisfaction score with postoperative analgesic effect (using a 5-point Likert scale, including five levels: Very Dissatisfied, Dissatisfied, Neutral, Satisfied, Very Satisfied)

    Time frame: from operation to 48 hours after operation

  6. Distress Thermometer

    Distress Thermometer (DT),0-10,Higher scores indicate worse condition.

    Time frame: from enrollment to 30 days after operation

  7. Generalized Anxiety Disorder 7-item Scale (GAD-7)

    0-21,Higher scores indicate worse anxiety symptoms

    Time frame: from enrollment to 30 days after operation

  8. Patient Health Questionnaire 2-item Scale (PHQ-2)

    0-6,Higher scores indicate worse depressive symptom severity

    Time frame: from enrollment to 30 days after operation

  9. Patient Health Questionnaire 9-item Scale (PHQ-9)

    0-27,Higher scores indicate worse depressive symptoms

    Time frame: from enrollment to 30 days after operation

  10. Impact of Event Scale - Revised (IES-R)

    0-88,Higher scores indicate worse post-traumatic stress symptoms (intrusions, avoidance, hyperarousal)

    Time frame: from enrollment to 30 days after operation

  11. Pittsburgh Sleep Quality Index (PSQI)

    0-21,Higher scores indicate worse sleep quality

    Time frame: from enrollment to 30 days after operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2026 to primary completion in Oct 2026, 6 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Dec 2025 → Apr 2026, primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Apr 17, 2026
StartActual
Apr 1, 2026was Dec 2025
Primary completionActual
Oct 30, 2026was Aug 2026
CompletionEst.
Nov 30, 2026was Aug 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 15, 2025→Apr 1, 2026
Nov 12, 2026
Primary completion
Aug 14, 2026→Oct 30, 2026 (actual)
Nov 12, 2026
Study completion
Aug 14, 2026→Nov 30, 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Dec 15, 2025→Apr 1, 2026
    Primary completion Aug 14, 2026→Oct 30, 2026 (now actual)
    Study completion Aug 14, 2026→Nov 30, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07537127
Responsible party
Chang Ren (associate chief physician, Peking Union Medical College Hospital) — Principal investigator
First posted
Apr 17, 2026
Start date
Apr 1, 2026
Primary completion
Oct 30, 2026
Completion
Nov 30, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Dr.
Contact
renchang@pumch.cn
+86 18612671870

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion